Cocrystal Pharma is a clinical-stage biotechnology company that develops small-molecule antiviral therapeutics for serious and chronic viral diseases using proprietary structure-based drug discovery technologies combining computational chemistry, medicinal chemistry, and X-ray crystallography. The company targets highly conserved viral replication proteins to create antiviral candidates with high resistance barriers, broad-spectrum efficacy, and favorable safety profiles across multiple viral indications including influenza, norovirus, coronavirus, and hepatitis C. Cocrystal's business model relies on advancing its pipeline through clinical trials and regulatory pathways while seeking development partners and capital to fund advancement, with revenue generation dependent on eventual FDA approval and commercialization of its product candidates.